RA'ANANA, Israel, Jan. 10,
2025 /PRNewswire/ -- Inspira Technologies OXY
B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the
"Company"), a leader in life-support technology innovation,
announced today that it is preparing for a potential production
ramp-up of its INSPIRA™ ART100 device. This strategic readiness
comes in light of the recent outbreak of human metapneumovirus
(hMPV) in China, which has
highlighted the growing need for advanced respiratory care
technologies globally.
Inspira is already in discussions with leading providers in
affected regions to evaluate demand for advance respiratory
solutions and deployment of the INSPIRA™ ART100 device, ensuring
rapid response capabilities in case of increased demand.
As global health authorities monitor the hMPV outbreak, Inspira™
believes that it is well-positioned to meet potential increased
demand for advanced respiratory support systems. Inspira is working
closely with suppliers to secure necessary raw materials and
components to meet potential demand spikes. The Company is
following the hMPV situation globally and working to adjust
production plans as needed.
"While hMPV is not a new virus, and experts indicate the current
outbreak is part of normal seasonal patterns, Inspira believes in
being prepared," said Dagi Ben-Noon, CEO of Inspira. "Our increased
production capacity will help ensure healthcare providers have
access to vital respiratory care equipment should the need
arise."
Inspira emphasizes that its preparedness measures are
precautionary and align with the Company's commitment to global
health readiness. The Company will work closely with health
authorities in affected regions and adjust its plans based on the
evolving situation.
Inspira™ Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical technology company
in the life support and respiratory treatment arena. The Company
has developed a breakthrough Augmented Respiration Technology
(INSPIRA™ ART), a groundbreaking device poised to revolutionize
the $19 billion mechanical ventilation market. With 20
million intensive care unit patients with acute respiratory failure
each year, many of whom rely on mechanical ventilators, the INSPIRA
ART offers a potential alternative by elevating and stabilizing
decreasing oxygen saturation levels in minutes without a
ventilator, with patients being awake during treatment. The INSPIRA
ART is being equipped with a clip-on HYLA™ blood sensor, a
real-time continuous blood monitoring technology, aiming to alert
physicians of changes in a patient's condition without the need for
intermittent actual blood samples, aiming to support physicians in
making informed decisions.
In June and July 2024,
respectively, the Company's INSPIRA™ ART100 system
has obtained FDA 510(k) clearance for use in CBP procedures, along
with the Israeli AMAR certification for both Extra-Corporeal
Membrane Oxygenation and Cardiopulmonary Bypass procedures.
The Company's other products and technologies, including the
INSPIRA ART also known as the INSPIRA™ ART500 or Gen 2, the
INSPIRA™ Cardi-ART portable modular device, VORTX™ Oxygen Delivery
System, and HYLA™ blood sensor, are currently being designed and
developed, and have not yet been tested or used in humans nor
approved by any regulatory entity.
For more information, please visit our corporate website
at https://inspira-technologies.com
Forward-Looking Statement Disclaimer This press release
contains express or implied forward-looking statements pursuant to
U.S. Federal securities laws. These forward-looking statements are
based on the current expectations of the management of the Company
only and are subject to a number of factors and uncertainties that
could cause actual results to differ materially from those
described in the forward-looking statements. For example, the
Company is using forward-looking statements when it discusses the
growing need for advanced respiratory care technologies and its
ability to adjust its plans to rapidly respond in case of increased
demand. These forward-looking statements and their implications are
based solely on the current expectations of the Company's
management and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those
described in the forward-looking statements. Except as otherwise
required by law, the Company undertakes no obligation to publicly
release any revisions to these forward-looking statements to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events. More detailed information
about the risks and uncertainties affecting the Company is
contained under the heading "Risk Factors" in the Company's annual
report on Form 20-F for the fiscal year ended December 31, 2023, filed with the U.S. Securities
and Exchange Commission (the "SEC"), which is available on the
SEC's website at www.sec.gov.
Contact: Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
MRK-ARS-113
Copyright © 2018-2025 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Logo:
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-preparing-production-in-response-to-spread-of-respiratory-virus-in-china-302347881.html
SOURCE Inspira Technologies
